Jacqueline E. Shea - 04 Mar 2026 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
Chief Executive Officer, Director
Signature
/s/ Jacqueline E. Shea
Issuer symbol
INO
Transactions as of
04 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 16:55:11 UTC
Previous filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shea Jacqueline Elizabeth Chief Executive Officer, Director 660 W. GERMANTOWN PIKE, PLYMOUTH MEETING /s/ Jacqueline E. Shea 05 Mar 2026 0001771498

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Common Stock Option Award +97,240 $0.000000* 97,240 04 Mar 2026 Common Stock 97,240 $1.73 Direct F1
transaction INO Restricted Stock Unit Award +78,760 $0.000000* 78,760 04 Mar 2026 Common Stock 78,760 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The vesting schedule for the 97,240 options granted on March 4, 2026 was as follows: 32,414 shares will vest on February 26, 2027; 32,413 shares will vest on February 26, 2028; 32,413 shares will vest on February 26, 2029.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 78,760 restricted stock units granted on March 4, 2026 was as follows: 26,254 shares will vest on February 26, 2027; 26,253 shares will vest on February 26, 2028; and 26,253 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.